checkAd

    EQS-News  229  0 Kommentare DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX TECHNOLOGY - Seite 3

    Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

     


    04.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com

    Language: English
    Company: Defence Therapeutics Inc.
    1680 - 200 Burrard St
    V6C3L6 Vancouver
    Canada
    E-mail: info@defencetherapeutics.com
    Internet: https://defencetherapeutics.com
    ISIN: CA24463V1013
    WKN: A3CN14
    Listed: Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto
    EQS News ID: 1849859

     
    End of News EQS News Service

    Lesen Sie auch

    1849859  04.03.2024 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1849859&application_name=news&site_id=wallstreet~~~257e03b8-9cbc-48b8-b6a5-ec526abf7b8e
    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-News DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX TECHNOLOGY - Seite 3 EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX TECHNOLOGY 04.03.2024 / 08:00 CET/CEST The issuer is solely responsible for the content …

    Artikel zu den Werten

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer